This week, STAT held a webinar entitled "What to Expect in Biotech 2018." The broadcast was hosted by Adam Feurstein, a senior biotech reporter, and Damian Garde, a national biotech reporter. The goal of the webinar was to provide a framework of the themes that are likely to shape the biotech sector in the coming year, as well to provide a look at biotech stocks in 2018.
This week, STAT held a webinar entitled “What to Expect in Biotech in 2018.” The broadcast was hosted by Adam Feurstein, a senior biotech reporter, and Damian Garde, a national biotech reporter. The goal of the webinar was to provide a framework of the themes that are likely to shape the biotech sector in the coming year, as well to provide a look at biotech stocks in 2018.
Garde highlighted the strides that both FDA Commissioner Scott Gottlieb, MD, and the FDA itself made in 2017 to expedite drug approvals and provide a more efficient, streamlined drug development process. Garde noted that it will be important to watch certain drugs after they’ve received expedited approval to make sure that drug efficacy or safety is still maintained through this quicker process.
Feurstein discussed potential upcoming FDA drug approvals throughout the year that could affect the biotech market, including:
According to a J.P. Morgan poll, 60% of investor respondents expect the biotech sector to outperform the broader market in 2018, and 84% expect an increase in mergers and acquisitions.
Presenters briefly mentioned biosimilars in the broadcast, stating that they’re here to stay, and companies that are making reference products will have to become innovative to keep up with the expected cost-savings from biosimilars, once more come to market.
As far as how the new tax reform bill could affect biotech companies, STAT believes that the increase in cash savings could result in either more mergers and acquisitions, or stock share buybacks later this year. According to the webcast, Amgen, Gilead Sciences, and Merck all hold more than $20 billion overseas.
The presentation closed with some drug launches and clinical trials to watch this year:
Drug launches:
Clinical Trials:
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.